The FDA announced on April 15, 2026, a July meeting to consider easing restrictions on seven peptides, including BPC-157 and TB-500, potentially moving them from Category 2 (restricted) to Category 1 for compounding by pharmacies.15
This follows RFK Jr.'s February 2026 statements calling the prior FDA restrictions on 14-19 peptides 'illegal' and pledging to loosen regulations.123
Peptides were placed in Category 2 in 2023 under Biden due to safety risks like cancer, organ damage, and lack of human testing data; they remain unapproved drugs.124
Influencers promote peptides for muscle building, injury healing, and anti-aging, but they lack FDA safety review and are banned in sports as doping agents.14
Reclassification would allow licensed pharmacies to produce them under prescription but does not approve them as drugs.24
Sources:
1. https://abcnews.com/US/wireStory/fda-weigh-easing-limits-unproven-peptides-favored-rfk-132059441
2. https://skytalegroup.com/news/a-turning-point-for-peptides-what-rfk-jrs-announcement-could-mean-for-the-future-of-wellness-and-longevity/
3. https://www.thelundreport.org/content/rfk-jr-may-reverse-peptide-ban-he-calls-illegal-former-fda-officials-say-he
4. https://www.wusf.org/2026-03-31/the-wellness-world-is-eager-for-rfk-jr-s-promised-move-on-peptides
5. https://www.upi.com/Top_News/US/2026/04/15/fda-peptides/3451776273052/